Indonesia Advances in Plasma-Derived Medicine Production

Breakthrough in Pharmaceutical Independence

SKPlasma Core Indonesia, a strategic collaboration between SK Plasma from SK Group Korea and Indonesia Investment Authority (INA), has successfully launched two critical plasma-derived pharmaceutical products: SK GammaBio and SK Albumin. This development represents a significant milestone in Indonesia's journey towards achieving pharmaceutical self-sufficiency and strengthening the nation's healthcare resilience.

Innovative Products Addressing Critical Needs

1. SK GammaBio: This intravenous immunoglobulin G (IVIG) product is designed to treat patients suffering from immune deficiencies, autoimmune diseases, and severe infections. As an essential medicine, it plays a crucial role in managing complex medical conditions that require advanced immunological support.
2. SK Albumin: This essential plasma protein is used in treating patients with severe medical conditions such as major burns, nephrotic syndrome, and hemorrhagic shock. The availability of this product will significantly enhance patient care in critical care settings.

Strategic Production and Supply Chain Development

The production process began on March 21, 2025, with the Indonesian Red Cross (PMI) Blood Donor Unit collaborating with Dr. Sardjito General Hospital to send the first batch of Indonesian donor plasma to SK Plasma's facilities in Korea for processing into Plasma-Derived Products (PODP). This collaboration marks the beginning of a robust supply chain that will help reduce Indonesia's reliance on imported plasma-derived medicines.

National Healthcare Impact

The launch of these products is particularly significant as it addresses multiple national healthcare priorities: reducing import dependency, enhancing the availability of critical medicines, and strengthening the country's pharmaceutical manufacturing capabilities. The development also demonstrates successful international collaboration in the healthcare sector, with technology and expertise transfer from SK Group to Indonesia.